Records containing: Relapsing Remitting Multiple Sclerosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-10-28A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™
-
CLINICAL_TRIALS study record update · 2024-09-19Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
-
CLINICAL_TRIALS study record update · 2024-06-04Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple
-
CLINICAL_TRIALS study record update · 2024-05-02A Real-World, Retrospective, Multicenter Study to Assess the Effectiveness and Safety of Mayzent® (Siponimod) in Chinese Patients With Relapsing Forms of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2024-02-05Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-01-16Randomized Controlled Trial on Intermittent Fasting in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-12-07Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-11-09Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-10-02Investigation of Subclinical Markers of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-09-22Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
-
CLINICAL_TRIALS study record update · 2023-05-09Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis / Améliorer Les capacités Cognitives Par tDCS Chez Les Patients Souffrants de sclérose en Plaques
-
CLINICAL_TRIALS study record update · 2023-04-27Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-04-21A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity
-
CLINICAL_TRIALS study record update · 2023-04-03A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-12-27Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS
-
CLINICAL_TRIALS study record update · 2022-12-21An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-11-03White Matter Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in Patients With Relapsing Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-09-28A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-07-25Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE
-
CLINICAL_TRIALS study record update · 2022-06-03A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS
-
CLINICAL_TRIALS study record update · 2022-05-18The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-04-28The Effect of Combined Progressive Functional Exercise on Contactin-1 and Contactin-2 Level in Mildly Disabled Persons With Multiple Sclerosis: A Randomized Controlled Trial
-
CLINICAL_TRIALS study record update · 2022-01-06A Single-Dose, Randomized, Open-Label, Two-Way Crossover, Bioequivalence Study of Bafiertam (Monomethyl Fumarate) 190 mg and Vumerity® (Diroximel Fumarate) 462 mg Delayed-Release Capsules in Fasting Healthy Male and Female Subjects
-
CLINICAL_TRIALS study record update · 2021-11-18An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® (Monomethyl Fumarate) From Dimethyl Fumarate (PERSIST)
-
CLINICAL_TRIALS study record update · 2021-11-09A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).